| Project Detail |
New immunotherapy targets cancerous cells that are immune to current treatment
Liver fibrosis is a scarring process resulting from the livers response to chronic injury or inflammation. It is caused by viruses, diseases, and alcoholism. Over time, it can lead to cirrhosis, a disruption in the organisation of the functional units of the liver that can eventually impede blood flow to the liver. Fibrosis and cirrhosis are also linked to the development of an aggressive and lethal form of liver cancer. The cancer is characterised by emergence of drug-resistant cell populations in response to the only systemic treatment currently available. Even worse, persistent treatment seems to speed tumour progression. HEPCAN is targeting those drug-resistant cell populations through the development of powerful monoclonal antibodies designed to decimate the resistors. |
